Cancer Prognostic Markers

• Melanoma:
  • 40% of whom will have BRAF V600-mutated tumors. These tumors are highly likely to respond to tyrosine kinase inhibitors targeting BRAF.
    • Vemurafenib (Zelboraf), Dabrafenib (Tafinlar), Encorafenib (Braftovi)
  • BRAF inhibitors are combined with MEK inhibitors and this combo actually has lower toxicity than single agent treatment:
    • Trametinib (Mekinist), Binimetinib (Mektovi)
• Non-small Cell Lung Ca:
  • Epidermal growth factor receptor (EGFR) status is used to determine eligibility for anti-EGFR tyrosine kinase inhibitors
    • eg: Erlotinib (Tarceva), Osimertinib (Tagrisso)

References:

• MKSAP
• Uptodate